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1400Minor ABO-Mismatches are Risk Factors for Acute
Graft-versus-Host Disease in Hematopoietic Stem Cell
Transplant Patients
Katarina Ludajic,1 Yesilda Balavarca,2 Heike Bickebo¨ller,2 Agathe Rosenmayr,1
Gottfried F. Fischer,1 Ingrid Fae,1 Peter Kalhs,3 David Pohlreich,3 Michal Kouba,3
Marie Dobrovolna,4 Hildegard T. Greinix3We investigated the impact of ABO and Rhesus (Rh) blood group matching on the outcome of hematopoietic
stem cell transplantation (HSCT) of 154 patients matched at 10/10 HLA loci with unrelated donors. ABO and
Rh, as potential risk factors, were modeled with the clinical outcome—acute and chronic graft-versus-host
disease (aGVHD, cGVHD), relapse, treatment-related mortality (TRM), and overall survival (OS)—by sim-
ple, multiple, and competing risk analyses. We found that minor ABO-mismatches represent a significant risk
factor for aGVHD (II-IV) with an estimated risk increase of almost 3-fold (hazard ratio [HR]5 2.92, 95% con-
fidence interval [CI]: 1.43-5.95, P5.003), and even 4-fold for aGVHD (III-IV) (HR5 4.24, 95% CI: 1.70-10.56,
P5.002), but not for other transplant endpoints. No significant association of the Rh matching status with
any of the HSCTendpoints was seen. These results suggest that ABO minor mismatches may play a role in
aGvHD pathophysiology, possibly by providing the setting for T cell activation and antibody mediated dam-
age. To decrease the risk of aGVHD, ABO matching should be considered in HSCT.
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Graft versus host disease (GVHD) is one of thema-
jor causes of morbidity and mortality after hematopoi-
etic stem cell transplantation (HSCT). The occurrence
of acute GVHD (aGVHD) in a substantial number of
patients given 10/10HLAmatched unrelated or sibling
donor grafts [1,2] indicates that antigens other thanma-
jor HLA may be relevant for the disease development.
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6/j.bbmt.2009.07.002[3], and they have been associated with the occurrence
and control of GVHD [4,5]. In addition, cytokine gene
polymorphisms and killer immunoglobuline-like re-
ceptor (KIR) genotypes of patients and donors have
been suggested to play a role in the aGVHD, albeit
via different mechanisms [6-8].
ABO antigens are carbohydrates expressed on red
blood cells and various epithelial and endothelial cells
[9]. Their synthesis depends on ABO glycosyltrans-
ferases, coded by more than 160 different alleles
described until now [10]. Regarding this polymor-
phism, Eiz-Vesper and colleagues [11] have recently
shown in vitro that different synthetic glycosyltransfer-
ase peptides can induce peptide-specific T cell
responses.This finding indicates potentialmHagprop-
erties of glycosyltransferases and supports previous
clinical reports, showing a significant association ofmi-
nor ABO-mismatches with increased risk of aGVHD
[12-14] and shorter overall survival (OS) in transplant
patients [14-16]. A recent large, multicenter study of
3103 patients given sibling grafts showed only an asso-
ciation of bidirectional ABO-mismatches with a higher
risk of severe aGVHD (III-IV), but not with aGVHD
(II-IV) or overall aGVHD [13]. There are, however,
several reports that showed no impact of ABO match-
ing status on HSCT outcome [17-19]. Rhesus (Rh)
mismatches were also either associated with the shorter
Table 1. Patient and Donor Characteristics by ABO Matching Status
ABO Matching Status
Characteristic Matched Major mm Minor mm Bidirectional mm Total
Fischer’s
Test P-Value
Number of patient/donor pairs (%) 58 (38) 30 (19) 44 (29) 22 (14) 154 na
Age patients, years, mean [range] 42 [19-62] 41 [18-61] 44 [19-63] 39 [21-55] 42 [18-63] na
Age donors, years, mean [range]* 36 [23-57] 35 [22-52] 37 [18-52] 36 [21-51] 36 [18-57] na
Sex (patient/donor), no.† (%)
F/F 10 (18) 6 (22) 12 (27) 2 (9) 30 (20) .17
F/M 15 (26) 7 (25) 9 (20) 7 (32) 38 (25)
M/F 11 (19) 4 (14) 3 (7) 8 (36) 26 (17)
M/M 21 (37) 11 (39) 20 (46) 5 (23) 57 (38)
CMV status (patient/donor), no. (%)
Pos/Pos 17 (29) 5 (16) 20 (45) 7 (32) 49 (32) .48
Pos/Neg 19 (33) 11 (37) 12 (27) 7(32) 49(32)
Neg/Pos 7 (12) 6 (20) 6 (14) 3 (13) 22 (14)
Neg/Neg 15 (26) 8 (27) 6 (14) 5 (23) 34 (22)
Disease, no. (%)
AL 26 (45) 17 (57) 13 (30) 8 (36) 64 (42) .17
CML 13 (22) 3 (10) 16 (36) 7 (32) 39 (25)
‘‘Other’’ 19 (33) 10 (33) 15 (34) 7(32) 51 (33)
Disease stage, no. (%)
Standard risk 35 (60) 15 (50) 21 (48) 12 (55) 83 (54) .61
High risk 23 (40) 15 (50) 23 (52) 10 (45) 71 (46)
Conditioning regime, no. (%)
Myeloablative 41 (71) 22 (73) 29 (66) 17 (77) 109 (71) .81
Reduced intensity 17 (29) 8 (27) 15 (34) 5 (23) 45 (29)
T cell depletion, no. (%)
T cell depleted 21 (36) 10 (33) 19 (43) 6 (27) 56 (36) .64
Non-T cell depleted 37 (64) 20 (67) 25 (57) 16 (73) 98 (64)
HSC source, no. (%)
BM 27 (47) 8 (27) 22 (50) 9 (41) 66 (43) .21
PBSCs 31 (53) 22 (73) 22 (50) 13 (59) 88 (57)
Cell dose infused: CD34+ cells 1026/kg
median [range]‡
5.46 [1.24-14.30] 6.88 [0.99-19.40] 5.04[1.65-12.00] 3.68 [1.16-10.90] 5.4 [0.99-19.4] na
GVHD prophylaxis, no. (%)
CsA + MTX 34 (59) 19 (63) 24 (54) 12 (55) 89 (58) .42
CsA + MMF 16 (27) 11 (37) 14 (32) 8 (36) 49 (32)
CsA 8 (14) 0 (0) 6 (14) 2 (9) 16 (10)
CMV indicates cytomegalovirus; CML, chronic myelogenous leukemia; GVHD, graft-versus-host disease; HSC, hematopoietic stem cell; BM, bone mar-
row; PBSCs, peripheral blood stem cells; CsA, cyclosporine; MTX, methotrexate; MMF, mycophenolate mofetil; y, year; no, number; mm, mismatches;
na, not applicable; F, female; M, male; AL, acute leukemia.
*Age of 4 donors are missing.
†Sex of 3 donors are missing.
‡Thirty-three data points are missing.
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However, to our knowledge, the effect of blood group
mismatches on the HSCT outcome has not been stud-
ied in unrelated, HLA-matched pairs.
We therefore examined the impact of ABO and Rh
patient-donor incompatibilities on the HSCT out-
come of 154 adult patients receiving 10/10 HLA-
matched grafts from unrelated donors at 2 transplant
centers in Vienna and Prague. Our aim was to investi-
gate if ABO and Rh matching status could be used for
risk estimations of HSCT endpoints in patients with
HLA class I and class II matched HSCT donors.MATERIALS AND METHODS
Study Population
The study population consisted of 154 consecutive
patients from Vienna (n5 122) and Prague (n5 32),who had undergone HSCT with unrelated donors.
Transplantations took place between September
1995 and December 2005. Data were analyzed as of
September 20, 2008. Median follow-up time of the pa-
tients alive was 74 months (range: 35-158 months). All
patients and donors were matched for HLA class I
(HLA-A, -B, -C) and class II (HLA-DRB1, -DQB1)
alleles, and patients transplanted in the Vienna center
were additionally matched forHLA-DRB3/4/5 alleles.
Retrospective typing showed that 14% of all pairs were
also matched for HLA-DPB1 alleles. HLA typing was
performed as previously described [22,23]; ABO and
Rh typing was performed by standard blood banking
methods [24]. Neither ABO nor Rh matching was
paid regard to in the donor selection process.
Patient and donor characteristics are shown in
Table 1. The ‘‘acute leukemias’’ (AL) group consisted
of 43 patients with acute myelogenous leukemia
(AML) and 21 patients with acute lymphoblastic
1402 Biol Blood Marrow Transplant 15:1400-1406, 2009K. Ludajic et al.leukemia (ALL). Thirty-nine patients had chronic my-
elogenous leukemia (CML). Other diseases included
26 patients with myelodysplastic syndrome (MDS),
13 patients with non-Hodgkin lymphoma (NHL), 1
with Hodgkin disease (HD), 2 with chronic lympho-
cytic leukemia (CLL), 1 with severe aplastic anemia
(SAA), 2 with myeloma, and 6 with chronic myelopro-
liferative disease. Eighty-three patients had ‘‘standard-
risk’’ disease, comprising CML in the first chronic
phase, AL and NHL in complete remission (CR),
and 71 ‘‘high risk’’ containing all other disease stages.
Conditioning therapies applied were either myeloabla-
tive (MA; n5 109) or reduced intensity (RIC n5 45).
In vivo T cell depletion (TCD) was performed by an-
tithymocyte globulin (ATG; Fresenius Biotech
GmbH, Munich, Germany) administration in 56 pa-
tients. Table 1 also gives the types and numbers of
transplanted stem cells and types of GVHD prophy-
laxis. The study has been approved by the Ethic Com-
mittees of both participating institutions. Informed
consent for hematopoietic stem cell (HSC) donation
and transplantation was obtained from all donors and
patients.
Clinical Endpoints
The endpoints analyzed in this report were
aGVHD and chronic GVHD (cGVHD), relapse,
treatment-related mortality (TRM), and OS. aGVHD
(grades II-IV) and aGVHD (grades III-IV) were sepa-
rately analyzed in statistical models, as were overall
and extensive cGVHD. Assessments of aGVHD and
cGVHD and supportive care during HSCT have
been previously described [25]. The minimum and
maximum times to overall aGVHD (I-IV) were 7
and 75 days, to cGVHD 80 and 107 days. The medical
staff performing GVHD assessment was exchanged
between the 2 participating centers to ensure consis-
tent evaluation of the disease. Relapse was defined as
recurrence of the primary disease after transplantation
based on immunohistochemistry criteria. TRM was
defined as death because of infections, aGVHD and
cGVHD, or organ toxicity without evidence of
relapse. OSwasmeasured from the transplantation un-
til death or the last follow-up.
Definitions of ABO and Rh Matching Status
ABO matched pairs had identical ABO blood
groups. In the major ABO mismatched group patients
had isoagglutinins directed against donor A or B anti-
gens, and in the minor ABO mismatch group donors
had isoagglutinins directed against patient A or B
antigens. In the bidirectional mismatched group,
both patients and donors had isoagglutinins directed
against each other. The presence of Rh factor in
patients and its absence in corresponding donors was
defined as a mismatch in graft-versus-host (GVH)direction, and its presence in donors and absence in
corresponding patients was defined as a mismatch in
host-versus-graft (HVG) direction.Statistical Analyses
Fisher’s exact test was used to test the association
between ABO matching status and other patients’
characteristics. The effects of ABO and Rh factors on
the aGVHD and cGVHD, relapse, TRM, and OS
were analyzed in simple and multiple Cox regression
models. From the multiple models we obtained the
effect of the ABO or Rh factor adjusted by a selected
set of significant clinical factors. The selection of sig-
nificant clinical factors was done as follows: simple
log-rank tests were performed for each of the clinical
variables, as listed in Table 1. Clinical variables having
P values\.20 were included in a subsequent multiple
Cox regression model in which the final set of signifi-
cant clinical factors was selected using a stepwise selec-
tion procedure. Age of patients and donors was first
dichotomized using the Classification and Regression
Trees (CART) [26,27]. CART divides a continuous
variable in 2 groups where the selected cutpoint yields
the largest differences in their effects on the outcome.
Additional competing risk analyses were performed to
evaluate the simple effects of the ABO and Rh factors
on aGVHD, cGVHD, TRM, and relapse. All the anal-
yses were performed for each of the endpoints inde-
pendently. Hazard ratios (HR) and 95% confidence
intervals (95% CI) were calculated in each analysis.
The significance level was set to .05 without adjust-
ment for multiple testing. All analyses were performed
using R software v. 2.7.1.RESULTS
ABO and Rh Blood Types of Patients andDonors
The frequencies of ABO blood groups in patients
were as follows: 56 patients (36%) had O, 59 (38%)
had A, 29 (19%) had B, and 10 (7%) had AB blood
group. In donors 67 (43%) had O, 63 (41%) had A,
15 (10%) had B, and 9 (6%) had AB blood group, re-
spectively. Blood group B has a higher frequency in
donors; however, the general comparison of ABO
group frequencies between patients and donors
showed no statistically significant difference. Fifty-
eight (38%) patients received ABO matched, and 96
(62%) received ABO mismatched transplants. Major
ABO-mismatch was detected in 30 (19%), minor
ABO-mismatch in 44 (29%), and bidirectional ABO-
mismatch in 22 (14%) patients (Table 1). Within the
major ABO-mismatched group patients’ isoaggluti-
nins were directed against donors’ A (n5 20),
B (n5 5), or AB antigens (n5 5). In minor ABO-
mismatched transplantations donors’ isoagglutinins
Aminor mismatched,      p=0.003
major mismatched,      p=0.23
bidirect. mismatched,  p=0.48
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Figure 1. Cumulative incidence of aGvHD (grades II-IV) (A) and aGvHD (grades III-IV) (B) according to the ABO matching status; p denotes probability.
Biol Blood Marrow Transplant 15:1400-1406, 2009 1403Impact of Minor ABO-Mismatches on HSCT Outcomewere directed against patients’ A (n5 29), B (n5 12),
or AB antigens (n5 3). Among 22 bidirectional mis-
matches, 16 patients had isoagglutinins directed
against donors’ A antigen, and 6 had isoagglutinins di-
rected against donors’ B antigen. No significant asso-
ciations between ABO matching status and other risk
factors were found (Table 1; Fisher’s test column), in-
dicating a fair distribution of patients within different
subgroups of risk factors. There were 119 patients
(78%) and 125 (81%) donors who were Rh positive,
whereas 34 (22%) patients and 29 (19%) donors were
Rh negative. There were 23 pairs (15%) Rh mis-
matched in GVH and 28 pairs (18%) mismatched in
HVG direction. In 1 patient Rh data were missing.aGVHD
aGVHD was assessed in 151 of 154 patients. Two
patients had missing onset dates and 1 patient died 1
day posttransplant. Overall aGVHD (I-IV) was
detected in 75 (50%), aGVHD (II-IV) in 51 (34%),
and aGVHD (III-IV) in 25 (17%) patients.
aGVHD(II-IV)was diagnosed in 16 (28%) patients
in the ABO-identical group, in 10 (33%) patients with
major ABO-mismatched donors, in 17 (40%) patients
withminor AB-mismatched donors, and in 8 (36%) pa-
tients with bidirectionally ABO-mismatched donors.
Cumulative incidences of aGVHD (II-IV) at day 75
were: 31% (95% CI: 17%-42%) for the ABO matched
group, 39% (95% CI: 18%-55%), for the major ABO-
mismatched group, 44% (95% CI: 26%-58%), for the
minor ABO-mismatched group, and 37% (95% CI:
13%-55%) for the bidirectionally ABO-mismatched
group (Figure 1A). Cumulative incidences for severe
aGVHD (III-IV) at day 75 were: 18% (95% CI: 5%-
28%) for the ABO-matched group, 10% (95% CI:
0%-23%) for the major ABO-mismatched group,
37% (95% CI: 18%-51%) for the minor ABO-mis-
matched group, and 14% (95%CI: 0%-28%) for bidi-
rectionally ABO-mismatched group (Figure 1B).
Simple and competing risk analyses did not show
an association of minor ABO-mismatches withaGVHD (II-IV). The minor mismatches, however, in-
creased the risk for aGVHD (III-IV) about 2.5-fold
(P5 .036, HR5 2.57, 95% CI: 1.06-6.19), as shown
by simple analysis. Adjustment by significant clinical
variables—TCD and age of donor—showed that pa-
tients with minor ABO-mismatched donors were at a
significantly increased risk of both aGVHD (II-IV)
(P5 .003, HR5 2.92, 95% CI: 1.43-5.95) and
aGVHD (III-IV) (P5 .002, HR5 4.24, 95% CI:
1.70-10.56), when compared to the ABO-matched
group. Rh matching status between patients and do-
nors was not associated with aGVHD.
Other variables associated with an increased risk of
aGVHD (II-IV) were TCD (P5 6.1 1026, HR5
0.16, 95% CI: 0.07-0.36), and donor age older than
37 years (P5 .024, HR5 0.51, 95% CI: 0.29-0.92).
The only other risk factor for aGVHD (III-IV) was
TCD (P5 .0005, HR5 0.14, 95% CI: 0.05-0.42).TRM
Thirty of 154 (19%) patients died of treatment-
related causes including infections in 23 and organ tox-
icity in 7 patients. Seven of the patients additionally
had aGVHD. TRM was observed in 8 (14%) patients
with ABO-matched, in 5 (17%) patients with major
ABO-mismatched, in 12 (27%) patients with minor
ABO-mismatched and in 5 (23%) patients with bidi-
rectionally ABO-mismatched donors, respectively.
The probability of TRM within 3 years was 15%
(95% CI: 5%-24%) for the ABO-matched group,
18% (95% CI: 2%-31%) for the major ABO-mis-
matched group, 28% (95% CI: 13%-40%) for the
minor ABO-mismatched group, and 25% (95% CI:
3%-42%) for the bidirectional ABO-mismatched pa-
tient group, respectively.
When the ABO and Rh matching status of the pa-
tients were modeled as risk factors for TRM by simple
analyses, no associations were seen. After relapse was
considered in the analysis as a competing risk for
TRM, the effect of the minor ABO-mismatches was
borderline significant (P5 .035, HR5 2.86, 95% CI:
Table 2. Influence of ABO and Rh Matching Status on HSCTOutcome According to Multiple Cox-Regression Models
Variable
aGVHD (II-IV) Relapse TRM OS
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
ABO mm 1.93 1.06-3.55 .032 0.83 0.47-1.47 .530 1.31 0.57-3.02 .530 1.32 0.78-2.25 .300
ABO major mm 1.63 0.74-3.62 .230 1.05 0.52-2.13 .890 1.34 0.43-4.15 .610 1.47 0.76-2.84 .470
ABO minor mm 2.92 1.43-5.95 .003 0.69 0.33-1.46 .330 1.28 0.49-3.37 .610 1.27 0.66-2.44 .470
TCD 0.16 0.07-0.36 <.00001 na na na na na na na na na
dage >37 years 0.51 0.29-0.92 .024 na na na na na na na na na
ABO bidirect. mm 1.37 0.58-3.22 .480 0.77 0.32-1.84 .560 1.32 0.43-4.07 .630 1.19 0.54-2.64 .670
Rh match stat (1) 1.68 0.82-3.46 .160 0.81 0.36-1.84 .610 0.96 0.33-2.83 .940 0.99 0.49-1.99 .980
Rh match stat (2) 1.70 0.87-3.34 .120 1.15 0.56-2.35 .710 1.19 0.50-2.84 .700 1.28 0.69-2.36 .440
na indicates not applicable; mm, mismatch; HR, hazard ratio; CI, confidence interval; P, probability; TRM, treatment-related mortality; OS, overall
survival; TCD, T cell depletion; dage, donor age; y, years.
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clinical factors in the multiple model, no significance
was found (Table 2).
Relapse and OS
Relapse was detected in 42 of 154 patients (34%),
and 65 patients (42%) had died by the end of the fol-
low-up. Cumulative incidence of relapse at 3 years
in the ABO-matched group was 41% (95% CI:
26%-53%), in the major ABO-mismatched group 46%
(95% CI: 23%-63%), in the minor ABO-mismatched
group 34% (95% CI: 15%-48%), and in the bidirec-
tionally mismatched group 37% (95% CI: 11%-
55%). Probability of survival at 3 years was 36%
(95% CI: 23%-47%) in the ABO-matched group,
53% (95% CI: 32%-68%) in the major ABO-mis-
matched group, 43% (95% CI: 26%-56%) in the mi-
nor ABO-mismatched group and 41% (95% CI:
16%-58%) in the bidirectionally mismatched group.
In summary, no statistical evidence of association of
the ABO or Rh matching status with relapse or OS
have been seen (Table 2).DISCUSSION
Here we report a significantly increased incidence
of aGVHD (II-IV) in patients given minor ABO-
mismatched stem cell grafts from HLA matched unre-
lated donors. The Rh matching status had no impact
on the transplantation outcome.
The stringent donor selection criteria applied:
10/10, and in the case of Vienna patients (79%) 12/12
HLA allele matching, suggest that mismatches in
mHags, rather than in HLA alleles, play a role in the
development of the aGVHD.
Recently it has been shown that A and B glycosyl-
transferase enzymes may act as mHags, eliciting T cell
response [11]. Considering that aGVHD is predomi-
nantly a T cell-mediated disease, it is conceivable
that donors’ T cells directed against patients’ A and
B glycosyltransferases play a role in the pathophysiol-
ogy of GVHD. In addition to the T cell response, inminor ABO-mismatched transplantation, donor A
and B specific antibodies may bind and cause damage
to the host endothelium, which expresses A and B an-
tigens [9]. In this transplant setting, the potential role
of antibodies coacting with T cells becomes evident.
Endothelium damage together with conditioning reg-
imens can trigger a cytokine storm, which enhances
GVHD in patients [14]. In major mismatched trans-
plantations, isoagglutinins do not damage endothe-
lium, and indeed, in that transplant setting we have
not observed an increased incidence of aGVHD using
bone marrow (BM) and peripheral blood stem cell
(PBSC)-derived stem cells. It still has to be investi-
gated whether this conclusion is true for cord blood
(CB) as a stem cell source. The B cell clones in cord
blood may not have been previously sensitized to
ABO antigens, and therefore GVHD related to ABO
mismatches may be of lesser significance.
Previously, we analyzed the effect of the HLA-
DPB1 matching status on the HSCT outcome in the
same patient cohort. We showed that HLA-DPB1
mismatches, as well as TCD and donor age, were sig-
nificant risk factors for aGVHD (II-IV) [23]. The asso-
ciation of minor ABO-mismatches with increased
aGVHD (II-IV) and severe aGVHD (III-IV) that we
report here is independent from the HLA-DPB1
matching status (data not shown).
Our findings are in line with a study showing an as-
sociation of minor ABO-mismatches with aGVHD
(II-IV) in 174 patients given T cell replete, HLA-
identical sibling grafts [28]. A similar association was
seen in a larger group of 481 T cell-depleted patients,
48% of which were HLA mismatched with corre-
sponding donors [12]. In yet a larger analysis of 562
patients, minor ABO-mismatches were shown to be
a risk factor for overall aGVHD (I-IV), but not for
aGVHD (II-IV) [16]. Other studies, however, showed
no effect of ABOmatching status between patients and
donors on aGVHD under similar conditions [13,18].
The substantial variability between the studies in the
degree of HLAmatching, joint analyses of both sibling
and unrelated transplantations, and different patient
treatment protocols might partly account for these
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play a role in GVHD development [29,30]. Ubiqui-
tously expressed mHags are targets for GVH effects
[31]. However, the increased aGVHD in minor
ABO-mismatched patients we report did not translate
into increased cGVHD (data not shown) or TRM of
patients. Also, no evidence of association of ABO or
Rh matching status of transplants on relapse or OS
was seen. This indicates that ABO antigens do not me-
diate GVL effects. Similar findings have been reported
by Klumpp and colleagues [18] and Seebach and col-
leagues [13], who analyzed a cohort of 3013 patients.
Most studies published to date suggest no difference
in relapse rates after transplantation with ABO-
mismatched grafts. Also, no associations of ABO
matching status with the OS were observed in large
studies of patients with HLA matched sibling or unre-
lated donors [13,19].
In our center it has previously been shown that the
subgroup of ABO minor mismatched patients receiv-
ing reduced intensity conditioning and cyclosporine
(CsA) as the only GVHD prophylaxis, have a signifi-
cantly higher TRM rate than patients in other sub-
groups. In our study, only 2 among the 154 patients
belonged to this risk group, but none developed
aGVHD or died because of the TRM. Important dif-
ferences, however, exist between the 2 study setups.
Most notably, the previous study included patients re-
ceiving both HLA matched and mismatched grafts
from corresponding related or unrelated donors, and
no adjustment for clinical factors was performed.
In summary, our study adds to the body of evidence
that minor ABO-mismatches represent a significant
risk factor for developing moderate and severe
aGVHDinHSCTwhere the selection of unrelated do-
nors was based on 10/10HLA allelematches. To lower
the risk of aGVHD, ABO matching should be taken
into account for donor selection. If no donors are avail-
able, minor ABO mismatches should be considered an
indication for intensification of GVHD prophylaxis.ACKNOWLEDGMENTS
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